Clinical Trial Results:
[18F]PSMA-11 PET/CT for prostate cancer – phase 3 clinical trial
Summary
|
|
EudraCT number |
2018-003168-29 |
Trial protocol |
BE |
Global end of trial date |
20 Sep 2020
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Dec 2021
|
First version publication date |
05 Dec 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
AGO/2018/003
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03911310 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Ghent University Hospital
|
||
Sponsor organisation address |
Corneel Heymanslaan 10, Gent, Belgium, 9000
|
||
Public contact |
Kathia De Man, Ghent University Hospital, 0032 093325461, kathia.deman@uzgent.be
|
||
Scientific contact |
Kathia De Man, Ghent University Hospital, 0032 093325461, kathia.deman@uzgent.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
20 Sep 2021
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
20 Sep 2020
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To determine the position of [18F]PSMA-11 PET/CT within the field of available radiotracers for diagnosis of prostate cancer. For this, the diagnostic performances of [18F]PSMA-11 will be compared to those of the current state-of-the-art radiotracer [68Ga]PSMA-11.
|
||
Protection of trial subjects |
- 18F]PSMA-11 and [68Ga]PSMA-11 are injected in a very low quantity to perform the PET scans. Consequently, product-related adverse reactions are not to be expected.
- as CT contrast is used in this trial, allergic reactions or a tempory slight reduction in kidney function might occur. In this regard, patients with a history of anaphylactic shock after CT contrast, as well as patients with a serum creatinine concentration > 2.0 mg/dL or estimated glomerular filtration rate < 30 ml/min, are not allowed to participate in this trial. In addition, the renal risk is further reduced by keeping the dose of contrast medium as low as possible during the study (dose calculation based on weight class) and keeping the patient sufficiently hydrated.
- The study drug taken in this study may pose an unprecedented risk to an embryo or foetus. Therefore, it is important that the patient avoid pregnancy with a partner and to use contraception (using a condom and possibly additional contraception by the partner) for up to 90 days after the study. The patients participating in this trial also commit to tell their partner that they are participating in this study and to inform the partner of the possible risk to the unborn child.
- Both the PET and the CT scan use ionising radiation, which leads to a certain radiation exposure for the patient. Although the patient received 2 PET/CT scans, radiation exposure is minimized by performing only one diagnostic CT scan, and by promoting excretion of the radiotracer.
- in case the patient experiences any discomfort, the patient will receive appropriate treatment
|
||
Background therapy |
- Iodixanol CT contrast --> to perform the diagnostic CT scan - Furosemide (in case that patient is not contra-indicated) --> to promote diuresis after radiotracer administration - physiological saline --> to promote diuresis after radiotracer administration | ||
Evidence for comparator |
Comparator: [68Ga]PSMA-11 evidence: Bois F, Noirot C, Dietemann S, et al. [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. Am J Nucl Med Mol Imaging. 2020;10(6):349-374. Published 2020 Dec 15. | ||
Actual start date of recruitment |
25 Apr 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 96
|
||
Worldwide total number of subjects |
96
|
||
EEA total number of subjects |
96
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
19
|
||
From 65 to 84 years |
77
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
- a maximum of 12 weeks was foreseen between the time of signing the informed consent and acquiring both ([18F]PSMA-11 and [68Ga]PSMA-11) PET/CT scans. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Inclusion criteria: Patients diagnosed with prostate cancer, either in the setting of diagnosis of biochemical recurrence after previous treatment, or at primary diagnosis and staging Exclusion criteria: Age < 18 years - Physically or mentally unfit to perform the sequential procedures - Refusal of patient to be informed about accidental f | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
PET CT scans (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind [1] | |||||||||||||||
Roles blinded |
Subject, Data analyst | |||||||||||||||
Blinding implementation details |
Concerning the order of the PET scans, half of the patients will be first scanned (= 1st period) with [18F]PSMA-11 and subsequently (=2nd period, maximum three weeks later) with [68Ga]PSMA-11. The scan order in the remaining group of patients will be reversed. Identity of the PET scans will be blind to the patients, the recruiting physicians, and the nuclear medicine physicians interpreting the images. Therefore, after PET/CT reconstruction, raditracer identity details are deleted.
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Ga-PSMA / F-PSMA | |||||||||||||||
Arm description |
1st PET CT scan: 68Ga-PSMA-11 2nd PET CT scan: 18F-PSMA-11 | |||||||||||||||
Arm type |
comparator followed by experimental | |||||||||||||||
Investigational medicinal product name |
68Ga-PSMA-11
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
2.0 +- 0.2 MBq/kg (single bolus intravenous injection)
|
|||||||||||||||
Investigational medicinal product name |
18F-PSMA-11
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
2.0 + 0.2 MBq/kg body weight (single intravenous bolus injection)
|
|||||||||||||||
Arm title
|
F-PSMA / Ga-PSMA | |||||||||||||||
Arm description |
1st PET CT: F-PSMA 2nd PET CT: Ga-PSMA | |||||||||||||||
Arm type |
experimental followed by comparator | |||||||||||||||
Investigational medicinal product name |
18F-PSMA-11
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
2.0 + 0.2 MBq/kg body weight (single intravenous bolus injection)
|
|||||||||||||||
Investigational medicinal product name |
68Ga-PSMA-11
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
2.0 +- 0.2 MBq/kg (single bolus intravenous injection)
|
|||||||||||||||
Notes [1] - The roles blinded appear to be inconsistent with a double blind trial. Justification: clinical trial coordinators and nuclear department secretary are not blinded as they participate in the randomisation process For safety reasons, the staff members that prepare the individual patient radiotracer dose (syringe) and the staff members that administer the dose are also not blinded. These staff members are not involved in the data analysis process |
||||||||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Ga-PSMA / F-PSMA
|
||
Reporting group description |
1st PET CT scan: 68Ga-PSMA-11 2nd PET CT scan: 18F-PSMA-11 | ||
Reporting group title |
F-PSMA / Ga-PSMA
|
||
Reporting group description |
1st PET CT: F-PSMA 2nd PET CT: Ga-PSMA |
|
||||||||||
End point title |
Evaluation of the non-inferiority of [18F]PSMA-11 compared to [68Ga]PSMA-11 with respect to the number of positive PET scans. Hereby, a positive PET scan is defined as a scan showing at least one suspected lesion. | |||||||||
End point description |
The non-inferiority of [18F]PSMA-11 will be investigated based on a Tango's score two-sided 95% confidence interval (CI) for a difference of proportions of positive scans of [18F]PSMA-11 compared to [68Ga]PSMA-11 with matched pairs. Non-inferiority will be concluded if the lower limit of this CI is larger than 0.10 (non-inferiority limit).
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
|
|||||||||
|
||||||||||
Statistical analysis title |
Tango's score two-sided 95% confidence interval (C | |||||||||
Statistical analysis description |
Non-inferiority of 18F-PSMA-11 was investigated based on a Tango's score two-sided 95% confidence interval (CI) for a difference of proportions of positive scans of 18F-PSMA-11 compared to 68Ga-PSMA-11 with matched pairs. Non-inferiority was concluded if the lower limit of this CI is larger than -0.10 (non-inferiority limit).
|
|||||||||
Comparison groups |
F-PSMA / Ga-PSMA v Ga-PSMA / F-PSMA
|
|||||||||
Number of subjects included in analysis |
82
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
non-inferiority [1] | |||||||||
Method |
||||||||||
Parameter type |
confidence interval | |||||||||
Point estimate |
0
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-0.045 | |||||||||
upper limit |
0.045 | |||||||||
Notes [1] - 82 patients included in the trial. (period 1 Ga-PSMA and period 2 F-PSMA comprise the same group of patients; period 1 F-PSMA and period 2 Ga-PSMA comprise the same group of patients) |
|
|||||||||||||
End point title |
Evaluation of the superiority of [18F]PSMA-11 compared to [68Ga]PSMA-11 with respect to the number of positive PET scans. Hereby, a positive PET scan is defined as a scan showing at least one suspected lesion | ||||||||||||
End point description |
Superiority of 18F-PSMA-11 compared to 68Ga-PSMA-11 with respect to the number of positive PET scans was statistically assessed by applying a McNemar’s test on the proportions of positive PET scans in each group. Hereby, superiority was defined as a difference of minimum 10% in the proportions of positive PET scans (18F-PSMA-11 > 68Ga-PSMA-11).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11]
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
McNemar’s test | ||||||||||||
Statistical analysis description |
McNemar’s test on the proportions of positive PET scans in each group. Hereby, superiority is defined as a difference of minimum 10% in the proportions of positive PET scans (18F-PSMA-11 > 68Ga-PSMA-11).
|
||||||||||||
Comparison groups |
Ga-PSMA / F-PSMA v F-PSMA / Ga-PSMA
|
||||||||||||
Number of subjects included in analysis |
82
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
Method |
|||||||||||||
Parameter type |
confidence interval | ||||||||||||
Point estimate |
0
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.045 | ||||||||||||
upper limit |
0.045 |
|
|||||||||||||
End point title |
Evaluation of the superiority of [18F]PSMA-11 compared to [68Ga]PSMA-11 with respect to the total number of suspected prostate cancer lesions in corresponding ([68Ga]PSMA-11 vs [18F]PSMA-11) scans | ||||||||||||
End point description |
The Wilcoxon signed rank test was applied to investigate differences (number of suspected prostate cancer lesions and scoring of corresponding suspected lesions) between 18F-PSMA-11 and 68Ga-PSMA-11 scans. Hereby, the superiority was defined as a difference of minimum 10% (18F-PSMA-11 > 68Ga-PSMA-11).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Wilcoxon signed rank | ||||||||||||
Statistical analysis description |
The Wilcoxon signed rank test was applied to investigate differences with regard to the number of suspected prostate cancer lesions between 18F-PSMA-11 and 68Ga-PSMA-11 scans. Hereby, the superiority was defined as a difference of minimum 10% (18F-PSMA-11 > 68Ga-PSMA-11).
|
||||||||||||
Comparison groups |
Ga-PSMA / F-PSMA v F-PSMA / Ga-PSMA
|
||||||||||||
Number of subjects included in analysis |
82
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.431 [2] | ||||||||||||
Method |
Wilcoxon Signed rank | ||||||||||||
Confidence interval |
|||||||||||||
Notes [2] - no statistical difference was found |
|
|||||||||||||
End point title |
Evaluation of the superiority of [18F]PSMA-11 compared to [68Ga]PSMA-11 with respect to the scoring of corresponding ([68Ga]PSMA-11 vs [18F]PSMA-11) suspected lesions | ||||||||||||
End point description |
The Wilcoxon signed rank test was applied to investigate differences (number of suspected prostate cancer lesions and scoring of corresponding suspected lesions) between 18F-PSMA-11 and 68Ga-PSMA-11 scans. Hereby, the superiority was defined as a difference of minimum 10% (18F-PSMA-11 > 68Ga-PSMA-11).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Wilcoxon signed rank | ||||||||||||
Statistical analysis description |
The Wilcoxon signed rank test was applied to investigate differences with regard to scoring of corresponding suspected lesions between 18F-PSMA-11 and 68Ga-PSMA-11 scans. Hereby, the superiority was defined as a difference of minimum 10% (18F-PSMA-11 > 68Ga-PSMA-11).
|
||||||||||||
Comparison groups |
Ga-PSMA / F-PSMA v F-PSMA / Ga-PSMA
|
||||||||||||
Number of subjects included in analysis |
82
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.024 [3] | ||||||||||||
Method |
Wilcoxon Signed rank | ||||||||||||
Confidence interval |
|||||||||||||
Notes [3] - as p< 0.05 --> statistically significant result |
|
|||||||||||||
End point title |
Descriptive evaluation of [18F]PSMA-11 compared to [68Ga]PSMA | ||||||||||||
End point description |
Descriptive evaluation of the results of the scan analysis (number of lesions, impact on TNM score, ...)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Time Frame: 0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Evaluation of the diagnostic specificity of [18F]PSMA-11 compared to [68Ga]PSMA-11 | ||||||||||||
End point description |
This endpoint will be evaluated in a descriptive way, more specifically by a description of the number of positive scans (and/or positive lesions) that can be confirmed via an anatomopathological diagnosis, changes in PSA concentration or via MRI, and by comparison of these numbers between [18F]PSMA-11 and [68Ga]PSMA-11.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
0 to 180 days post [18F]PSMA-11 and [68Ga]PSMA-11 administration
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Evaluation of the safety of [18F]PSMA-11 administration: CTCAE 4.0 criteria | ||||||||||||
End point description |
Adverse events will be reported and scored (CTCAE 4.0 criteria) between the first dose administration of trial medication and the last trial related activity. From the time of radiotracer injection till completion of the PET/CT scan (for both [18F]PSMA-11 and [68Ga]PSMA-11), the site staff will visually observe and actively ask the patient whether or not he has observed any adverse effects. Although [18F]PSMA-11 is totally eliminated from the body within 9 hours post injection (= 10 x half-life of 47 ± 5 minutes), AE's occurring up to 24h after the second PET/CT scan will also be handled as such if spontaneously reported by the patient to the investigator.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
0 to 24 h post [18F]PSMA-11 and [68Ga]PSMA-11 administration
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Assessment of the interobserver variability with regard to the evaluation of the [18F]PSMA-11 and [68Ga]PSMA-11 PET scans | ||||||||||||
End point description |
This endpoint will be evaluated by determining a Light's kappa value
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
0 to 100 minutes post injection for both [18F]PSMA-11 and [68Ga]PSMA-11
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Light's kappa value | ||||||||||||
Statistical analysis description |
For the interobserver variability with regard to the evaluation of the 18F-PSMA-11 and 68Ga-PSMA-11 PET scans, a Light’s Kappa value was determined.
|
||||||||||||
Comparison groups |
Ga-PSMA / F-PSMA v F-PSMA / Ga-PSMA
|
||||||||||||
Number of subjects included in analysis |
82
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.00326 | ||||||||||||
Method |
light's kappa | ||||||||||||
Parameter type |
lights kappa | ||||||||||||
Point estimate |
0.6375
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.4587 | ||||||||||||
upper limit |
0.8162 |
|
|||||||||||||||||
Adverse events information
|
|||||||||||||||||
Timeframe for reporting adverse events |
0 to 24 h post [18F]PSMA-11 and [68Ga]PSMA-11 administration
|
||||||||||||||||
Adverse event reporting additional description |
AE's will be reported and scored between the first dose administration of trial medication and the last trial related activity. Active questioning for AE's during period that patient is at clinical trial site. Passive follow-up of AE's reported by the patient until 24 hours after 2nd PET/CT scan.
|
||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||
Dictionary name |
CTCAE | ||||||||||||||||
Dictionary version |
4.0
|
||||||||||||||||
Reporting groups
|
|||||||||||||||||
Reporting group title |
Nausea
|
||||||||||||||||
Reporting group description |
Nausea after CT contrast | ||||||||||||||||
|
|||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
11 drop-outs : 9 drop-outs before any study related handlings, 2 drop-outs after the first PET/CT scan (transport issue and loss of interest) scans of 2 patients not included in the analysis due to motion artefacts and technical issues |